BYL719

ESMO18: Novartis PI3K combo therapy boosts survival in subset of breast cancer patients
Fierce Biotech
Sat, 10/20/18 - 11:10 pm
Europe
Novartis
ESMO
AstraZeneca
breast cancer
BYL719
Good Phase III results for Novartis’ cancer drug (breast cancer)
GoinPharma
Sun, 08/26/18 - 12:05 pm
Novartis
clinical trials
breast cancer
BYL719
alpelisib
Novartis’ PI3K drug hits goal in phase 3 breast cancer trial, laying groundwork for talks with regulators
Fierce Biotech
Thu, 08/23/18 - 10:19 am
Novartis
PI3k inhibitor
BYL719
clinical trials
breast cancer